Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 15;12(6):e056522.
doi: 10.1136/bmjopen-2021-056522.

Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)

Affiliations

Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)

Pavel Osmancik et al. BMJ Open. .

Abstract

Introduction: Atrial fibrillation (AF), with a prevalence of 2%, is the most common cardiac arrhythmia. Catheter ablation (CA) has been documented to be superior to treatment by antiarrhythmic drugs (AADs) in terms of sinus rhythm maintenance. However, in obese patients, substantial weight loss was also associated with AF reduction. So far, no study has compared the modern non-invasive (AADs combined with risk factor modification (RFM)) approach with modern invasive (CA) treatment. The aim of the trial is to compare the efficacy of modern invasive (CA) and non-invasive (AADs with risk factor management) treatment of AF.

Methods and analysis: The trial will be a prospective, multicentre, randomised non-inferiority trial. Patients with symptomatic AF and a body mass index >30 will be enrolled and randomised to the CA or RFM arm (RFM+AAD) in a 1:1 ratio. In the CA arm, pulmonary vein isolation (in combination with additional lesion sets in non-paroxysmal patients) will be performed. For patients in the RFM+AAD arm, the aim will be a 10% weight loss over 6-12 months, increased physical fitness and a reduction in alcohol consumption. The primary endpoint will be an episode of AF or regular atrial tachycardia lasting >30 s. The secondary endpoints include AF burden, clinical endpoints associated with AF reoccurrence, changes in the quality of life assessed using dedicated questionnaires, changes in cardiorespiratory fitness and metabolic endpoints. An AF freedom of 65% in the RFM+AAD and of 60% in the CA is expected; therefore, 202 patients will be enrolled to achieve the non-inferiority with 80% power, 5% one-sided alpha and a non-inferiority margin of 12%.

Ethics and dissemination: The PRAGUE-25 trial will determine if modern non-invasive AF treatment strategies are non-inferior to CA. The study was approved by the Ethics Committee of the University Hospital Kralovske Vinohrady. Results of the study will be disseminated on scientific conferences and in peer-reviewed scientific journals. After the end of follow-up, data will be available upon request to principal investigator.

Trial registration number: ClinicalTrials.gov Registry (NCT04011800).

Keywords: Adult cardiology; NUTRITION & DIETETICS; Pacing & electrophysiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
CONSORT diagram of the study. AF, atrial fibrillation; BMI, body mass index; CONSORT, Consolidated Standards of Reporting Trials; QoL, quality of life.

References

    1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. . Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 2004;110:1042–6. 10.1161/01.CIR.0000140263.20897.42 - DOI - PubMed
    1. Chugh SS, Havmoeller R, Narayanan K, et al. . Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014;129:837–47. 10.1161/CIRCULATIONAHA.113.005119 - DOI - PMC - PubMed
    1. Piccini JP, Lopes RD, Kong MH, et al. . Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009;2:626–33. 10.1161/CIRCEP.109.856633 - DOI - PubMed
    1. Marrouche NF, Brachmann J, Andresen D, et al. . Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27. 10.1056/NEJMoa1707855 - DOI - PubMed
    1. Packer DL, Mark DB, Robb RA, et al. . Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261–74. 10.1001/jama.2019.0693 - DOI - PMC - PubMed

Publication types

Substances

Associated data